ALK and non-small cell lung carcinoma: However, direct head‐to‐head clinical trials of the efficacy and safety of different ALK inhibitors are limited.9, 10 Only four meta‐analysis studies have analyzed the efficacy and safety of ALKi (two studies on crizotinib, one on alectinib and one on overall ALKi) for treating ALK‐positive NSCLC.11, 12, 13, 14 Hu et al and Qian et al pooled the progression‐free survival (PFS) and overall response rate (ORR) from 13 clinical trials of NSCLC patients undergoing different lines of treatments with crizotinib.